相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cancer Statistics, 2021
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Estimated annual prevalence, medical service utilization and direct costs of lung cancer in urban China
Dawei Zhu et al.
CANCER MEDICINE (2021)
Multiple Resistance Mechanisms to Tyrosine Kinase Inhibitors in EGFR Mutated Lung Adenocarcinoma: A Case Report Harboring EGFR Mutations, MET Amplification, and Squamous Cell Transformation
Rossella Bruno et al.
FRONTIERS IN ONCOLOGY (2021)
Squamous cell carcinoma transformation after acquired resistance to osimertinib in a patient with lung adenocarcinoma harboring uncommon EGFR mutation
Chi-Lu Chiang et al.
JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION (2020)
Squamous cell transformation as a mechanism of acquired resistance to tyrosine kinase inhibitor in EGFR-mutated lung adenocarcinoma: a report of two cases
Hironori Uruga et al.
RESPIROLOGY CASE REPORTS (2020)
Paired genomic analysis of squamous cell carcinoma transformed from EGFR-mutated lung adenocarcinoma
Sehhoon Park et al.
LUNG CANCER (2019)
Outcome of EGFR-mutated adenocarcinoma NSCLC patients with changed phenotype to squamous cell carcinoma after tyrosine kinase inhibitors: A pooled analysis with an additional case
Elisa Roca et al.
LUNG CANCER (2019)
Effect of osimertinib treatment on lung adenocarcinoma with squamous cell transformation harboring the T790M mutation: A case report and literature review
Fumihiro Yamaguchi et al.
MOLECULAR AND CLINICAL ONCOLOGY (2019)
An EGFR-mutated Lung Adenocarcinoma Undergoing Squamous Cell Carcinoma Transformation Exhibited a Durable Response to Afatinib
Mitsuo Sato et al.
INTERNAL MEDICINE (2018)
Osimertinib for Secondary T790M-Mutation-Positive Squamous Cell Carcinoma Transformation After Afatinib Failure
Moonkyoo Kong et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Osimertinib for Epidermal Growth Factor Receptor Mutation–Positive Lung Adenocarcinoma That Transformed to T790M-Positive Squamous Cell Carcinoma
Naoyuki Okabe et al.
Journal of Thoracic Oncology (2017)
Synchronous occurrence of squamous-cell carcinoma transformation and EGFR exon 20 S768I mutation as a novel mechanism of resistance in EGFR-mutated lung adenocarcinoma
Lucia Longo et al.
LUNG CANCER (2017)
Squamous cell transformation and EGFR T790M mutation as acquired resistance mechanisms in a patient with lung adenocarcinoma treated with a tyrosine kinase inhibitor: A case report
Rossella Bruno et al.
ONCOLOGY LETTERS (2017)
Squamous Cell Carcinoma Transformation Concurrent with Secondary T790M Mutation in Resistant EGFR-Mutated Adenocarcinomas
Agita Jukna et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Strategies to Improve Outcomes of Patients with EGRF-Mutant Non-Small Cell Lung Cancer: Review of the Literature
Caicun Zhou et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
The International Epidemiology of Lung Cancer: Latest Trends, Disparities, and Tumor Characteristics
Ting-Yuan David Cheng et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Mechanisms of resistance to EGFR-targeted drugs: lung cancer
Floriana Morgillo et al.
ESMO OPEN (2016)
Histologic Evolution From Adenocarcinoma to Squamous Cell Carcinoma After Gefitinib Treatment
Min-Shu Hsieh et al.
ANNALS OF THORACIC SURGERY (2015)
Transformation to a squamous cell carcinoma phenotype of an EGFR-mutated NSCLC patient after treatment with an EGFR-tyrosine kinase inhibitor
Justine L. Kuiper et al.
JOURNAL OF CLINICAL PATHOLOGY (2015)
Histologic Transformation from Adenocarcinoma to Squamous Cell Carcinoma as a Mechanism of Resistance to EGFR Inhibition
Pavel A. Levin et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Lecia V. Sequist et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
Are adenosquamous lung carcinomas a simple mix of adenocarcinomas and squamous cell carcinomas, or more complex at the molecular level?
Kristell Bastide et al.
LUNG CANCER (2010)
分享论文
